FFP
NVCR icon

FourThought Financial Partners’s NovoCure NVCR Stock Holding History

FourThought Financial Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,683
Closed -$267K – 590
2025
Q3 		$267K Buy
+20,683
New +$276K 0.02% 389

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FourThought Financial Partners's NVCR Position: Q4 2025 in Review

FourThought Financial Partners sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 20,683 shares — an estimated $267K sold.

FourThought Financial Partners first reported a position in NVCR in Q3 2025 and held it in 1 quarter. The position peaked at $267K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • FourThought Financial Partners reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • FourThought Financial Partners sold 20,683 NovoCure shares in Q4 2025, an estimated $267K.
  • FourThought Financial Partners first reported a position in NovoCure in Q3 2025 and held it in 1 quarter.
  • FourThought Financial Partners's NovoCure position peaked at $267K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on FourThought Financial Partners's 13F filing for Q4 2025, filed 6 Feb 2026.